Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia

Last updated: November 24, 2023
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

3

Condition

Influenza

Treatment

N-acetyl cysteine

5% Dextrose

Clinical Study ID

NCT03900988
NAC Influenza/Hui/2019
  • Ages > 18
  • All Genders

Study Summary

Seasonal influenza epidemics are important causes of morbidity and mortality. Cytokine dysregulation, with high levels of pro-inflammatory cytokines, occurs in patients with severe influenza. Early therapy with a neuraminidase inhibitor (NAI) is associated with better outcome in patients hospitalized with influenza, but significant mortality occurs despite use of antivirals. N-acetylcysteine (NAC) is a modified form of the amino acid cysteine, with anti-oxidant properties. NAC was shown to inhibit the production of pro-inflammatory molecules in lung epithelial cells infected with influenza viruses. Previous case report showed that high dose NAC, administered as continuous intravenous infusion, was effective and safe in improving the clinical outcomes. We aim to perform a randomized controlled trial to evaluate the therapeutic role of adjunctive NAC in the clinical management of patients with influenza complicated by lower respiratory tract involvement and abnormal respiratory status. Such information when available may reveal the potential of NAC for optimization of management of severe influenza, and provide important insights into future adjunctive therapy research.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • influenza A and B virus infections confirmed by polymerase chain reaction (PCR) and/orimmunofluorescence assays,
  • hospitalized for the management of severe manifestations of influenza,
  • initiation of oseltamivir,
  • clinical evidence of lower respiratory tract infection (e.g. shortness of breath,tachypnea, oxygen desaturation <93% on room air, crepitations on auscultation,infiltrations or consolidations on chest radiograph)
  • written informed consent (by the subjects, or from their next of kin if the subjectsare unable to provide written consent at the time of enrollment)

Exclusion

Exclusion Criteria:

  • use of immunosuppressants (e.g. post-chemotherapy, post-transplant, autoimmunediseases) other than systemic corticosteroids
  • known immuno-compromised conditions (e.g. active haematological malignancies, HIV/AIDSpatients who are on antiretroviral therapy and CD4 cell count < 200),
  • pregnancy
  • lactation,
  • end-stage renal failure
  • hepatic failure
  • cardiac failure
  • patients on anticoagulation (except prophylactic dose of low molecular weightheparin),
  • patients with scheduled major surgery within 2 weeks (NAC may affect blood clotting),
  • patients who have received macrolide antibiotics and NSAID for 1 week prior toenrolment due to their immuno-modulating effects.
  • Use of investigational anti-influenza antivirals and blood products

Study Design

Total Participants: 160
Treatment Group(s): 2
Primary Treatment: N-acetyl cysteine
Phase: 3
Study Start date:
May 08, 2023
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Prince of Wales Hospital

    Hong Kong,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.